| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-11-11 |
| タイトル |
|
|
タイトル |
Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Immune checkpoint inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
tyrosine kinase inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
favourable risk |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
renal cell carcinoma |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
OKI, MASAHARU
OHBA, KOJIRO
MUKAE, YUTA
MATSUDA, TSUYOSHI
NAKANISHI, HIROMI
MITSUNARI, KENSUKE
MATSUO, TOMOHIRO
MOCHIZUKI, YASUSHI
IMAMURA, RYOICHI
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background/Aim: Currently, a combination of an immune checkpoint inhibitor (ICI) and a tyrosine kinase inhibitor (TKI) is the most widely used first-line treatment for metastatic renal cell carcinoma (mRCC). However, patients in the IMDC favourable risk group have been reported to have a relatively good prognosis, even when they undergo TKI monotherapy. The aim of this study was to evaluate whether ICI/TKI combination therapy or TKI monotherapy is more effective in patients with favourable IMDC risk. Patients and Methods: We retrospectively reviewed 11 patients with favourable IMDC risk who underwent ICI/TKI combination therapy and 12 who underwent TKI monotherapy as first-line treatment for mRCC at our institution between April 2008 and September 2024 and compared their characteristics and treatment outcomes. The endpoints were overall survival (OS), progression-free survival (PFS) and treatment response, which was assessed using the overall response rate (ORR) and disease control rate (DCR). The safety of the regimens was evaluated using the incidences of grade ≥3 adverse events (AEs) and treatment discontinuation. Results: There was a significant difference between the groups regarding the duration of follow-up (24.4 months for the ICI/TKI group vs. 65.9 months for the TKI group, p=0.01), but no other differences were noted in the characteristics of the patients. The PFS and OS of the groups did not significantly differ following initial treatment. The ORR did not significantly differ, but tended to be better in the ICI/TKI group. The incidence of grade ≥3 AEs and the discontinuation of treatment owing to AEs did not significantly differ but tended to be higher in the TKI group. Conclusion: Based on its superiority with respect to ORR and AE at our Institution, ICI/TKI therapy should be considered whenever possible, even in patients in the IMDC favourable risk group. |
|
言語 |
en |
| 書誌情報 |
en : In Vivo
巻 39,
号 6,
p. 3445-3452,
発行日 2025-10-29
|
| 出版者 |
|
|
出版者 |
International Institute of Anticancer Research |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0258-851X |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.21873/invivo.14142 |
| 権利 |
|
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. ©2025 The Author(s). Anticancer Research is published by the International Institute of Anticancer Research. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
In Vivo, 39(6), pp.3445-3452; 2025 |
|
言語 |
en |
IV39_3445.pdf (1.1 MB)
